Across TCGA pan-cancer cohorts, TOR3A mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated TOR3A data layer compared with 23 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher TOR3A mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated TOR3A expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LUAD show a favorable association.

PDAC, CCRCC, and LUAD are the cancer types where TOR3A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	All	0.598	0.908	.004	9	view →
CCRCC	DFS	Median	III,IV	1.000	0.451	.032	6	view →
LUAD	DFS	Tertile	II,III,IV	0.990	0.803	.041	4	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: TOR3A tumor-vs-normal RNA expression · all TOR3A data types